Australia's most trusted
source of pharma news
Thursday, 19 February 2026
Posted 19 February 2026 AM
CSL is looking to offload its IL-6 monoclonal antibody clazakizumab to Eli Lilly in a deal worth $100 million-plus, on the grounds that it retains rights to a cardiovascular indication.
Under the terms of the licensing agreement, CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardiovascular events in patients with end-stage kidney disease (ESKD).

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.